Summary
Gland Pharma has secured a strategic Manufacturing and Supply Agreement with a major global pharmaceutical company for sterile injectable products, covering 55 SKUs across three sites. This deal has an annualised revenue potential of $90-100 million upon commercialisation, with revenue generation expected to commence in 2029.